UNSPSC 51142045: Ziconotide acetate

This classification denotes a nonnarcotic analgesic with the molecular formula C102H172N36O32S7.C2H4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T2I226K69M. European Medicines Agency schedules ziconotide acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25201. The term ziconotide acetate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule ziconotide acetate under HS 29349990 and SITC 51579.

Ziconotide acetate bears US NLM identifiers UMLS ID C1577317 and NCI Concept Code C95275. SMILES: As of Q4 2014, ZICONOTIDE ACETATE remains US FDA's Preferred Term for this commodity.

UNSPSC 51142045 Ziconotide acetate is a Commodity code that in practice does not align with recent state and local procurement activity; the code's nominal scope is a specific pharmaceutical compound, but the three most recent opportunities tagged under it concern naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products—none of which are ziconotide acetate. State and local governments buying under this code tag do not appear to be procuring the specific drug named, but rather are using the code as a catch-all for pharmaceutical sourcing and community health initiatives. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing consortia (Minnesota Multistate Cooperative Purchasing Alliance). The work spans pharmaceutical distribution, drug safety equipment provision, and pharmacy benefit program design.

Recent activity clusters in Texas and Florida, with Minnesota-administered cooperative purchasing covering multiple states including Oregon. The Seminole County IFB (solicitation IFB60459723LAS, due July 26, 2023) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas HHS Commission issued RFI HHS0017013 (due April 3, 2026) to gather vendor capabilities for a direct-to-manufacturer prescription program with self-insured employers and state agencies. The Minnesota Department of Administration, on behalf of MMCAP, released an RFP (solicitation S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities, with contracts effective July 1, 2026. The mismatch between the code's nominal drug and the actual procurements suggests either a classification error in the source data or a broad institutional use of this code for pharmaceutical sourcing generally.